Motor complications in Parkinson disease: Clinical manifestations and management

Journal of the Neurological Sciences

Volumn 266, Issue 1-2, 2008, Pages 204-215

  Bhidayasiri, Roongroj ^a,b,c   Truong, Daniel D ^c  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Parkinson's and Movement Disorder Institute   (United States)

Author keywords

Complex fluctuations; Dopaminomimetic therapy; Dyskinesia; Motor complications; Parkinson disease

Indexed keywords

AMANTADINE; ANTACID AGENT; BACLOFEN; BOTULINUM TOXIN; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYPOCHOLESTEROLEMIC AGENT; IRON; LEVODOPA; LITHIUM; PLACEBO; PYRIDOXINE; ROTIGOTINE; TOLCAPONE;

ARTICLE; BRAIN SURGERY; CLINICAL FEATURE; DIARRHEA; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DYSKINESIA; DYSTONIA; GAIT DISORDER; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SUSTAINED DRUG RELEASE;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DYSKINESIAS; HUMANS; MOVEMENT DISORDERS; PARKINSON DISEASE; RISK FACTORS;

EID: 38749096245     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.08.028     Document Type: Article

References (154)

1. Obeso J.A., Grandas F., Vaamonde J., Luquin M.R., Artieda J., Lera G., et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39 Suppl 2 (1989) 11-19
2. Van Gerpen J.A., Kumar N., Bower J.H., Weigand S., and Ahlskog J.E. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmstead County, Minnesota, 1976-1990. Arch Neurol 63 (2006) 205-209
3. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
4. Golbe L.I. Young-onset Parkinson's disease: a clinical review. Neurology 41 (1991) 168-173
5. Schrag A., Ben-Shlomo Y., Brown R., Marsden C.D., and Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 13 (1998) 885-894
6. Marsden C.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
7. Goetz C.G. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol 91 (2003) 213-228
8. Sweet R.D., and McDowell F.H. The "on-off" response to chronic L-DOPA treatment of parkinsonism. Adv Neurol 5 (1974) 331-338
9. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., and Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology 55 Suppl 4 (2000) S13-S20
10. Marsden C.D., and Parkes J.D. "On-Off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet i (1976) 292-296
11. Schwab R.S., and Ziepper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Arch Psych Neurol 150 (1965) 345-357
12. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 (2000) 1484-1491
13. Group P.S. Pramipexole vs Levodopa as initial treatment for Parkinson disease. JAMA 284 (2000) 1931-1938
14. Rascol O., Payoux P., Ory F., Ferreira J.J., Brefel-Courbon C., and Montastruc J.L. Limitations of current Parkinson's disease therapy. Ann Neurol 53 Suppl 3 (2003) S3-S12 [discussion S12-5]
15. Muenter M.D., and Tyce G.M. L-Dopa therapy of Parkinson's disease: plasma L-Dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46 (1971) 231-239
16. Hauser R.A., Olanow C.W., and Koller W.C. Time course of washout of symptomatic medication in Parkinson's disease. Neurology 44 (1994) 259
17. Nutt J.G., and Holford N.H. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39 (1996) 561-573
18. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
19. Zappia M., Oliveri R.L., Montesanti R., Rizzo M., Bosco D., Plastino M., et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 52 4 (1999) 763-767
20. Nutt J.G., Woodward W.R., Carter J.H., and Gancher S.T. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49 11 (1992) 1123-1130
21. Cotzias G.C., Van Woert M.H., and Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967) 374-379
22. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 2 (1990) 340-345
23. Muenter M.D., Sharpless N.S., Tyce G.M., and Darley F.L. Patterns of dystonia ("I-D-I and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 52 (1977) 163-173
24. Nutt J.G., and Woodward W.R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36 6 (1986) 739-744
25. Horstink M.W., Zijlmans J.C., Pasman J.W., Berger H.J., and van't Hof M.A. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 53 3 (1990) 224-226
26. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
27. Lhermitte F., Agid Y., and Signoret J.L. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 35 (1978) 261-263
28. Tolosa E.S., Martin W.E., Cohen H.P., and Jacobson R.L. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 25 (1975) 177-183
29. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5 7 (2002) 627-628
30. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 10 (2001) 710-719
31. Melamed E. Early morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 36 (1979) 308-310
32. Nausieda P.A., Weiner W.J., and Klawans H.L. Dystonic foot response of parkinsonism. Arch Neurol 37 (1980) 132-136
33. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., and Anderson J.L. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 310 (1984) 483-488
34. Marsden C.D., Parkes J.D., and Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden C.D., and Fahn S. (Eds). Movement disorders (1982), Butterworths, London 96-110
35. Scheife R.T., Schumock G.T., Burstein A., Gottwald M.D., and Luer M.S. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 57 10 (2000) 953-962
36. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 55 Suppl 1 (1998) 1-9
37. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 Pt 12 (2004) 2747-2754
38. de la Fuente-Fernandez R., Schulzer M., Mak E., Calne D.B., and Stoessl A.J. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127 Pt 4 (2004) 888-899
39. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 8 (2001) 577-588
40. Chase T.N., Oh J.D., and Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology 51 2 Suppl 2 (1998) S30-S35
41. Chase T.N., Mouradian M.M., and Engber T.M. Motor response complications and the function of striatal efferent systems. Neurology 43 12 Suppl 6 (1993) S23-S27
42. Schrag A., Hovris A., Morley D., Quinn N., and Jahanshahi M. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 18 (2003) 1250-1256
43. Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 23 (2000) 252-261
44. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 123 (2000) 2297-2305
45. Grandas F., Galiano M.L., and Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246 12 (1999) 1127-1133
46. Quinn N., Critchley P., and Marsden C.D. Young-onset Parkinson's disease. Mov Disord 2 (1987) 73-91
47. Sossi V., de la Fuente-Fernandez R., Schulzer M., Adams J., and Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129 Pt 4 (2006) 1050-1058
48. Hauser R.A., McDermott M.P., and Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63 12 (2006) 1756-1760
49. Poewe W.H., Lees A.J., and Stern G.M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 11 (1986) 1528-1530
50. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56 5 (1999) 529-535
51. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 9 (2004) 997-1005
52. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 70 (2006) 419-426
53. Blin J., Bonnet A.M., and Agid Y. Does levodopa aggravate Parkinson's disease?. Neurology 38 9 (1988) 1410-1416
54. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 7 (1985) 949-956
55. Langston J.W., and Ballard Jr. P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309 5 (1983) 310
56. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 4587 (1983) 979-980
57. Cedarbaum J.M., Gandy S.E., and McDowell F.H. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41 5 (1991) 622-629
58. Bergmann K.J., Mendoza M.R., and Yahr M.D. Parkinson's disease and long-term levodopa therapy. Adv Neurol 45 (1987) 463-467
59. Kostic V.S., Marinkovic J., Svetel M., Stefanova E., and Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 9 1 (2002) 9-14
60. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 55 12 Suppl 6 (2000) S2-S6
61. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 66 7 (2006) 983-995
62. Goetz C.G., Poewe W., Rascol O., and Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20 5 (2005) 523-539
63. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 13 11 (2006) 1186-1202
64. Widner H. Strategies to modify levodopa treatment. Adv Neurol 91 (2003) 229-236
65. Dodel R.C., Singer M., Kohne-Volland R., Szucs T., Rathay B., Scholz E., et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 14 3 (1998) 299-312
66. Pahwa R., Lyons K., McGuire D., Silverstein P., Zwiebel F., Robischon M., et al. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 12 5 (1997) 677-681
67. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Econ 5 1 (1986) 1-30
68. Welsh M.D., Dorflinger E., Chernik D., and Waters C. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord 15 3 (2000) 497-502
69. Rinne U.K., Larsen J.P., Siden A., and Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt study group. Neurology 51 5 (1998) 1309-1314
70. Adler C.H., Singer C., O'Brien C., Hauser R.A., Lew M.F., Marek K.L., et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone fluctuator study group III. Arch Neurol 55 8 (1998) 1089-1095
71. Rajput A.H., Martin W., Saint-Hilaire M.H., Dorflinger E., and Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49 4 (1997) 1066-1071
72. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson study group. Ann Neurol 42 5 (1997) 747-755
73. Mannisto P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51 4 (1999) 593-628
74. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 5 (1994) 913-919
75. Gordin A., Kaakkola S., and Teravainen H. Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 91 (2003) 237-250
76. Assal F., Spahr L., Hadengue A., Rubbia-Brandt L., and Burkhard P.R. Tolcapone and fulminant hepatitis. Lancet 352 9132 (1998) 958
77. Colosimo C. The rise and fall of tolcapone. J Neurol 246 10 (1999) 880-882
78. Hauser R.A. Levodopa/carbidopa/entacapone (Stalevo). Neurology 62 1 Suppl 1 (2004) S64-S71
79. Myllyla V., Haapaniemi T., Kaakkola S., Kinnunen E., Hartikainen P., Nuutinen J., et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand 114 3 (2006) 181-186
80. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 8 (2006) 677-687
81. Silver D.E. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother 4 4 (2004) 589-599
82. Olanow C.W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9 1 (1994) 40-47
83. Lieberman A., Ranhosky A., and Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49 1 (1997) 162-168
84. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole study group. Neurology 51 4 (1998) 1057-1062
85. Metman L.V., Gillespie M., Farmer C., Bibbiani F., Konitsiotis S., Morris M., et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24 3 (2001) 163-169
86. LeWitt P.A., Lyons K.E., and Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68 16 (2007) 1262-1267
87. LeWitt P.A., and Nyholm D. New developments in levodopa therapy. Neurology 62 1 Suppl 1 (2004) S9-S16
88. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 1 (2003) 93-101
89. Rascol O., Lees A.J., Senard J.M., Pirtosek Z., Montastruc J.L., and Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 19 3 (1996) 234-245
90. Ahlskog J.E., Muenter M.D., McManis P.G., Bell G.N., and Bailey P.A. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 63 9 (1988) 876-886
91. Pahwa R., Busenbark K., Huber S.J., Michalek D., Hubble J.P., and Koller W.C. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43 4 (1993) 677-681
92. Hutton J.T., Morris J.L., Roman G.C., Imke S.C., and Elias J.W. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Arch Neurol 45 8 (1988) 861-864
93. Goetz C.G., Tanner C.M., Klawans H.L., Shannon K.M., and Carroll V.S. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology 37 5 (1987) 875-878
94. Kurth M.C., Tetrud J.W., Irwin I., Lyness W.H., and Langston J.W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 43 5 (1993) 1036-1039
95. Kolls B.J., and Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 29 5 (2006) 292-301
96. Golbe L.I., Lieberman A.N., Muenter M.D., Ahlskog J.E., Gopinathan G., Neophytides A.N., et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 11 1 (1988) 45-55
97. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62 2 (2005) 241-248
98. Hauser R.A., Russ H., Haeger D.A., Bruguiere-Fontenille M., Muller T., and Wenning G.K. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 29 6 (2006) 322-330
99. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 5 (2002) 604-612
100. Linazasoro G. Anticholinergics and dyskinesia. Mov Disord 9 6 (1994) 689
101. Hauser R.A., and Olanow C.W. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 8 4 (1993) 512-514
102. Snow B.J., Macdonald L., McAuley D., and Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23 2 (2000) 82-85
103. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., and Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75 1 (2004) 141-143
104. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., and Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 5 (1998) 1323-1326
105. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 3 (2004) 381-388
106. Grosset K.A., Bone I., and Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 20 11 (2005) 1502-1507
107. Rodriguez-Oroz M.C., Obeso J.A., Lang A.E., Houeto J.L., Pollak P., Rehncrona S., et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128 Pt 10 (2005) 2240-2249
108. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355 9 (2006) 896-908
109. Lhermitte F., Agid Y., Signoret J.L., and Studler J.M. ["Beginning and end of dose" dyskinesias caused by L-DOPA]. Rev Neurol (Paris) 133 5 (1977) 297-308
110. Krack P., Pollak P., Limousin P., Benazzouz A., Deuschl G., and Benabid A.L. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 122 Pt 6 (1999) 1133-1146
111. Poewe W.H., Lees A.J., and Stern G.M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 23 1 (1988) 73-78
112. Reynolds N.A., Wellington K., and Easthope S.E. Rotigotine: in Parkinson's disease. CNS Drugs 19 11 (2005) 973-981
113. Pacchetti C., Albani G., Martignoni E., Godi L., Alfonsi E., and Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 10 3 (1995) 333-336
114. Giron Jr. L.T., and Koller W.C. Methods of managing levodopa-induced dyskinesias. Drug Saf 14 6 (1996) 365-374
115. Leon A.S., and Spiegel H.E. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 12 7 (1972) 263-267
116. Pfeiffer R., and Ebadi M. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients. J Neurochem 19 9 (1972) 2175-2181
117. Contin M., Riva R., Martinelli P., Albani F., and Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 54 4 (1998) 303-308
118. Baruzzi A., Contin M., Riva R., Procaccianti G., Albani F., Tonello C., et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 10 6 (1987) 527-537
119. Sakakibara R., Odaka T., Uchiyama T., Asahina M., Yamaguchi K., Yamaguchi T., et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 2 (2003) 268-272
120. Jost W.H., and Eckardt V.F. Constipation in idiopathic Parkinson's disease. Scand J Gastroenterol 38 7 (2003) 681-686
121. Edwards L.L., Quigley E.M., and Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42 4 (1992) 726-732
122. Valenzuela J.E. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology 71 6 (1976) 1019-1022
123. Leenders K.L., Poewe W.H., Palmer A.J., Brenton D.P., and Frackowiak R.S. Inhibition of l-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20 2 (1986) 258-262
124. Brogden R.N., Carmine A.A., Heel R.C., Speight T.M., and Avery G.S. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24 5 (1982) 360-400
125. Soykan I., Sarosiek I., Shifflett J., Wooten G.F., and McCallum R.W. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 12 6 (1997) 952-957
126. Stocchi F., Quinn N.P., Barbato L., Patsalos P.N., O'Connel M.T., Ruggieri S., et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol 17 1 (1994) 38-44
127. Stocchi F., Barbato L., Bramante L., Bonamartini A., and Ruggieri S. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Funct Neurol 9 5 (1994) 259-264
128. Steiger M.J., Stocchi F., Bramante L., Ruggieri S., and Quinn N.P. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol 15 6 (1992) 501-504
129. Djaldetti R., and Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 39 3 (1996) 400-404
130. Colosimo C., Merello M., Hughes A.J., Sieradzan K., and Lees A.J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 60 6 (1996) 634-637
131. Pincus J.H., and Barry K.M. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 44 10 (1987) 1006-1009
132. Pincus J.H., and Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 44 3 (1987) 270-272
133. Pietz K., Hagell P., and Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 65 5 (1998) 709-716
134. Nilsson D., Hansson L.E., Johansson K., Nystrom C., Paalzow L., and Aquilonius S.M. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 97 3 (1998) 175-183
135. Stibe C.M., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1 8582 (1988) 403-406
136. Colzi A., Turner K., and Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 5 (1998) 573-576
137. Stocchi F., Bramante L., Monge A., Viselli F., Baronti F., Stefano E., et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 60 (1993) 653-655
138. Vaamonde J., Luquin M.R., and Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 114 Pt 1B (1991) 601-617
139. Kurth M.C., Tetrud J.W., Tanner C.M., Irwin I., Stebbins G.T., Goetz C.G., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43 9 (1993) 1698-1703
140. Sage J.I., Trooskin S., Sonsalla P.K., Heikkila R., and Duvoisin R.C. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24 1 (1988) 87-89
141. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 Pt 9 (2002) 2058-2066
142. Nyholm D., and Aquilonius S.M. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 27 5 (2004) 245-256
143. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernas H., Nystrom C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26 3 (2003) 156-163
144. Nilsson D., Nyholm D., and Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 104 6 (2001) 343-348
145. Weaver F., Follett K., Hur K., Ippolito D., and Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 103 6 (2005) 956-967
146. Kleiner-Fisman G., Herzog J., Fisman D.N., Tamma F., Lyons K.E., Pahwa R., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl 14 (2006) S290-S304
147. Giladi N., Treves T.A., Simon E.S., Shabtai H., Orlov Y., Kandinov B., et al. Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 108 1 (2001) 53-61
148. Giladi N. Freezing of gait. Clinical overview. Adv Neurol 87 (2001) 191-197
149. Schaafsma J.D., Balash Y., Gurevich T., Bartels A.L., Hausdorff J.M., and Giladi N. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol 10 4 (2003) 391-398
150. Giladi N., Gurevich T., Shabtai H., Paleacu D., and Simon E.S. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 248 7 (2001) 572-576
151. Giladi N., McDermott M.P., Fahn S., Przedborski S., Jankovic J., Stern M., et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56 12 (2001) 1712-1721
152. Jiang Y., and Norman K.E. Effects of visual and auditory cues on gait initiation in people with Parkinson's disease. Clin Rehabil 20 1 (2006) 36-45
153. Dietz M.A., Goetz C.G., and Stebbins G.T. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord 5 3 (1990) 243-247
154. Siemers E.R., Shekhar A., Quaid K., and Dickson H. Anxiety and motor performance in Parkinson's disease. Mov Disord 8 4 (1993) 501-506